 |
Epoprostenol |
|---|---|
| Trade Name | Flolan |
| Orphan Indication | Replacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage |
| USA Market Approval | USA |
| USA Designation Date | 1984-03-29 00:00:00 |
| Sponsor | Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, North Carolina, 27709 |
